Celebrating the progression of treatment for Inherited Retinal Diseases on Rare Disease Day

Video

Dr Aleksandra Rachitskaya discusses how the treatment landscape for Inherited Retinal Diseases has changed and her hope for the future.

On Rare Disease Day, Dr Aleksandra Rachitskaya talks about how far treatment has come for Inherited Retinal Diseases. Once an untreatable diagnosis, Inherited Retinal Diseases now have an approved gene therapy option as well as more therapeutics under investigation.

Video transcript

Dr Rachitskaya: Hi, my name is Aleksandra Rachitskaya, and I'm a retina surgeon at Cleveland Clinic Cole Eye Institute. On this Rare Disease Day, I'm really excited about the future of Inherited Retinal Diseases. It used to be that Inherited Retinal Diseases were a type of diagnosis one was given, and there was not much hope in terms of treatment. A lot of patients would progressively lose vision and had to rely on low vision devices.

But these days, we do have an approved gene therapy, and also a lot of clinical trials focusing on gene therapy for a variety of Inherited Retinal Diseases. So on this Rare Disease Day, I think the future of Inherited Retinal Diseases as it comes to gene therapy is bright, and I'm excited to be part of that.

Note: This transcript has been lightly edited for clarity.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.